RPL22L1

Across TCGA pan-cancer cohorts, RPL22L1 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of RPL22L1’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where RPL22L1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RPL22L1 is over-expressed in tumor, although a few such as HNSC and PDAC show the opposite, repressed pattern.

LSCC, HNSC, and CCRCC are the cancer types where RPL22L1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL22L1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	All	+0.608	<.001	9	view →
HNSC	Male	III,IV	−0.556	<.001	9	view →
CCRCC	All	II,III,IV	+0.448	<.001	9	view →
COAD	Female	III,IV	+0.938	<.001	8	view →
PDAC	Female	II,III,IV	−1.713	<.001	7	view →
LUAD	Male	All	+0.625	<.001	7	view →
OV	All	All	+0.739	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

RPL22L1–LSCC

Open the LSCC breakdown →